Gonadal damage and options for fertility preservation in female and male cancer survivors

Asian Journal of Andrology

Volumn 8, Issue 5, 2006, Pages 515-533

  Maltaris, Theodoros ^a,c   Koelbl, Heinz ^a   Seufert, Rudolf ^a   Kiesewetter, Franklin ^b   Beckmann, Matthias W ^b   Mueller, Andreas ^b   Dittrich, Ralf ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cancer treatment; Cryopreservation; Fertility preservation; Male infertility; Ovarian tissue; Reproduction; Semen preservation

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CISPLATIN DERIVATIVE; CLOMIFENE CITRATE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MERCAPTOPURINE; MITOXANTRONE; ORAL CONTRACEPTIVE AGENT; PREDNISONE; PROCARBAZINE; PROGESTERONE; SPHINGOSINE 1 PHOSPHATE; TAMOXIFEN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ABDOMINAL RADIOTHERAPY; AGING; AMENORRHEA; ANEUPLOIDY; APOPTOSIS; AZOOSPERMIA; BLADDER CANCER; BLADDER SURGERY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CLINICAL TRIAL; CRYOPRESERVATION; DRUG MECHANISM; DRUG SAFETY; FEMALE STERILITY; FERTILIZATION IN VITRO; FETUS MALFORMATION; GONADAL DISEASE; HODGKIN DISEASE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INFERTILITY; INFERTILITY THERAPY; INTRAUTERINE GROWTH RETARDATION; IONIZING RADIATION; LAPAROSCOPY; LEUKEMIA; LOW BIRTH WEIGHT; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE STERILITY; MALNUTRITION; NONHUMAN; OVARY DISEASE; OVARY FOLLICLE; OVARY INSUFFICIENCY; OVULATION INDUCTION; PRECOCIOUS PUBERTY; PREMATURE LABOR; PREMATURE OVARIAN FAILURE; PROSTATE CANCER; PROSTATE SURGERY; RADIATION DOSE; RADIATION INJURY; RECTUM CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPERM PRESERVATION; SPONTANEOUS ABORTION; TESTIS CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER; WHOLE BODY RADIATION;

ADULT; CHILD; FEMALE; FERTILITY; HUMANS; INFERTILITY; MALE; NEOPLASMS; OVARIAN NEOPLASMS; OVARY; SURVIVORS; TESTICULAR NEOPLASMS; TESTIS;

EID: 33747607058     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2006.00206.x     Document Type: Review

References (183)

1. Muller J. Impact of cancer therapy on the reproductive axis. Horm Res 2003; 59: 12-20.
2. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999; 33: 29-33.
3. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001; 7: 394-403.
4. Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J Clin 2005; 55: 211-28.
5. Stern CJ, Toledo MG, Gook DA, Seymour JF. Fertility preservation in female oncology patients. Aust N Z J Obstet Gynaecol 2006; 46: 15-23.
6. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-31.
7. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10: 251-66.
8. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005; 353: 64-73.
9. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989; 51: 651-4.
10. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004; 428: 145-50.
11. Johnson M, Everitt BJ. Ovarian Function. In: Essential Reproduction. Oxford: Blackwell Scientific PubliPations;1988: p 75-100.
12. Thomson AB, Critchley HO, Kelnar CJ, Wallace WH. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab 2002; 16: 311-34.
13. Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J Natl Cancer Inst Monogr 2005; 34: 36-9.
14. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7: 535-43.
15. Gosden RG, Wade JC, Fraser HM, Sandow J, Faddy MJ. Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod 1997; 12: 2483-8.
16. Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998; 21: 287-90.
17. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373-85.
18. Wallace WH, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: The radiosensitivity of the human oocyte. Br J Radiol 1989; 62: 995-8.
19. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: A review. Cancer 1976; 37 (Suppl 2): 1111-25.
20. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol 1999; 150: 245-54.
21. Wallace WH, Thomson AB. Preservation of fertility in children treated for cancer. Arch Dis Child 2003; 88: 493-6.
22. Critchley HO, Bath LE, Wallace WH. Radiation damage to the uterus-review of the effects of treatment of childhood cancer. Hum Fertil (Camb) 2002; 5: 61-6.
23. Larsen EC, Schmiegelow K, Rechnitzer C, Loft A, Muller J, Andersen AN. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand 2004; 83: 96-102.
24. Holm K, Nysom K, Brocks V, Hertz H, Jacobsen N, Muller J. Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. Bone Marrow Transplant 1999; 23: 259-63.
25. Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005; 34: 64-8.
26. Li FP, Gimbrere K, Gelber RD, Sallan SE, Flamant F, Green DM, et al. Outcome of pregnancy in survivors of Wilms' tumor. JAMA 1987; 257: 216-9.
27. Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer 1989; 43: 399-402.
28. Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 1986; 45: 443-59.
29. Swerdlow AJ, Jacobs PA, Marks A, Maher EJ, Young T, Barber JC, et al. Fertility, reproductive outcomes, and health of offspring, of patients treated for Hodgkin's disease: An investigation including chromosome examinations. Br J Cancer 1996; 74: 291-6.
30. Fenig E, Mishaeli M, Kalish Y, Lishner M. Pregnancy and radiation. Cancer Treat Rev 2001; 27: 1-7.
31. Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994; 78: 1282-6.
32. Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328: 87-94.
33. Apperley JF, Reddy N. Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev 1995; 9: 93-116.
34. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: High-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998; 22: 989-94.
35. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002; 9: 466-72.
36. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-64.
37. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto, MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993; 8: 2080-7.
38. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999; 33: 65-76.
39. Katoh MA, Cain KT, Hughes LA, Foxworth LB, Bishop JB, Generoso WM. Female-specific dominant lethal effects in mice. Mutat Res 1990; 230: 205-17.
40. Mailhes JB. Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes. Mutat Res 1995; 339: 155-76.
41. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001; 16: 632-7.
42. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr 2005; 34: 21-5.
43. Meirow D, Schenker JG. Cancer and male infertility. Hum Reprod 1995; 10: 2017-22.
44. Hallak J, Kolettis PN, Sekhon VS, Thomas AJ Jr, Agarwal A. Sperm cryopreservation in patients with testicular cancer. Urology 1999; 54: 894-9.
45. Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online 2004; 9: 673-9.
46. Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999; 17: 941-7.
47. Agarwal A, Allamaneni SS. Disruption of spermatogenesis by the cancer disease process. J Natl Cancer Inst Monogr 2005; 34: 9-12.
48. Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease. a prospective study. JAMA 1981; 245: 1323-8.
49. Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001; 12: 1307-11.
50. Viviani S, Ragni G, Santoro A, Perotti L, Caccamo E, Negretti E, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27: 1389-92.
51. Barr RD, Clark DA, Booth JD. Dyspermia in men with localized Hodgkin's disease. a potentially reversible, immune-mediated disorder. Med Hypotheses 1993; 40: 165-8.
52. Hallak J, Sharma RK, Thomas AJ Jr, Agarwal A. Why cancer patients request disposal of cryopreserved semen specimens posttherapy: A retrospective study. Fertil Steril 1998; 69: 889-93.
53. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: Natural history and prognosis. Clin Oncol (R Coll Radiol) 1989; 1: 75-9.
54. Shalet SM, Didi M, Ogilvy-Stuart AL, Schulga J, Donaldson MD. Growth and endocrine function after bone marrow transplantation. Clin Endocrinol (Oxf) 1995; 42: 333-9.
55. Centola GM, Keller JW, Henzler M, Rubin P. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. J Androl 1994; 15: 608-13.
56. Gordon, W Jr, Siegmund, K, Stanisic TH, McKnight B, Harris IT, Carroll PR, et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys 1997; 38: 83-94.
57. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: Damage and recovery. J Natl Cancer Inst Monogr 2005; 34: 12-7.
58. Martin RH, Hildebrand K, Yamamoto J, Rademaker A, Barnes M, Douglas G, et al. An increased frequency of human sperm chromosomal abnormalities after radiotherapy. Mutat Res 1986; 174: 219-25.
59. Fattibene P, Mazzei F, Nuccetelli C, Risica S. Prenatal exposure to ionizing radiation: Sources, effects and regulatory aspects. Acta Paediatr 1999; 88: 693-702.
60. Brougham MF, Kelnar CJ, Sharpe RM, Wallace HB. Male fertility following childhood cancer: Current concepts and future therapies. Asian J Androl 2003; 5: 325-37.
61. Thomson AB, Campbell AJ, Irvine DC, Anderson RA, Kelnar CJ, Wallace WH. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: A case-control study. Lancet 2002; 360: 361-7.
62. Chatterjee R, Haines GA, Perera DM, Goldstone A, Morris ID. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000; 15: 762-6.
63. Li FP, Fine W, Jaffe N, Holmes GE, Holmes FF. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst 1979; 62: 1193-7.
64. Hawkins MM, Smith RA, Curtice LJ. Childhood cancer survivors and their offspring studied through a postal survey of general practitioners: preliminary results. J R Coll Gen Pract 1988; 38: 102-5.
65. Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl JMed 1987; 317: 1315-21.
66. Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 1975; 2: 156-7.
67. Witt KL, Bishop JB. Mutagenicity of anticancer drugs in mammalian germ cells. Mutat Res 1996; 355: 209-34.
68. Choudhury RC, Jagdale MB, Misra S. Potential transmission of the cytogenetic effects of cisplatin in the male germline cells of Swiss mice. J Chemother 2000; 12: 352-9.
69. Sjoblom T, Parvinen M, Lahdetie J. Stage-specific DNA synthesis of rat spermatogenesis as an indicator of genotoxic effects of vinblastine, mitomycin C and ionizing radiation on rat spermatogonia and spermatocytes. Mutat Res 1995; 331: 181-90.
70. Albanese R. Mammalian male germ cell cytogenetics. Mutagenesis 1987; 2: 79-85.
71. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000; 169: 123-31.
72. Liang JC, Sherron DA, Johnston D. Lack of correlation between mutagen-induced chromosomal univalency and aneup-loidy in mouse spermatocytes. Mutat Res 1986; 163: 285-97.
73. van Buul PP, Goudzwaard JH. Bleomycin-induced structural chromosomal aberrations in spermatogonia and bone-marrow cells of mice. Mutat Res 1980; 69: 319-24.
74. Genesca A, Caballin MR, Miro R, Benet J, Bonfill X, Egozcue J. Human sperm chromosomes. long-term effect of cancer treatment. Cancer Genet Cytogenet 1990; 46: 251-60.
75. Martin RH, Ernst S, Rademaker A, Barclay L, Ko E, Summers N. Analysis of sperm chromosome complements before, during, and after chemotherapy. Cancer Genet Cytogenet 1999; 108: 133-6.
76. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, et al. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 1997; 16: 74-8.
77. Puscheck E, Philip PA, Jeyendran RS. Male fertility preservation and cancer treatment. Cancer Treat Rev 2004; 30: 173-80.
78. McCall ML, Keaty EC, Thompson JD. Conservation of ovarian tissue in the treatment of carcinoma of the cervix with radical surgery. Am J Obstet Gynecol 1958; 75: 590-600.
79. Morice P, Castaigne D, Haie-Meder C, Pautier P, El Hassan, J, Duvillard P, et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. Fertil Steril 1998; 70: 956-60.
80. Bidzinski M, Lemieszczuk B, Zielinski J. Evaluation of the hormonal function and features of the ultrasound picture of transposed ovary in cervical cancer patients after surgery and pelvic irradiation. Eur J Gynaecol Oncol 1993; 14 (Suppl): 77-80.
81. Morice P, Thiam-Ba R, Castaigne D, Haie-Meder C, Gerbaulet A, Pautier P, et al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum Reprod 1998; 13: 660-3.
82. Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: An underused procedure. Am J Obstet Gynecol 2003; 188: 367-70.
83. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: The role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002; 187: 93-105.
84. Pereyra, Pacheco B, Mendez, Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol 2001; 81: 391-7.
85. Oktay K, Sonmezer M, Oktem O. 'Ovarian cryopreservation versus ovarian suppression by GnRH analogues: Primum non nocere' - reply. Hum Reprod 2004; 19: 1681-3.
86. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000; 169: 123-31.
87. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19: 159-62.
88. Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003; 10: 291-9.
89. Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146: 1-14.
90. Jonat W. The role of LHRH analogs in premenopausal breast cancer. In: Lunenfeld, B, editor. GnRH analogues: The state of the art 2001. A summary of the 6th International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 2001. New York: Parthenon; 2002.
91. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58: 849-51.
92. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983; 52: 988-93.
93. Montz FJ, Wolff A J, Gambone JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 1991; 51: 2124-6.
94. Tilly JL. Molecular and genetic basis of normal and toxicant-induced apoptosis in female germ cells. Toxicol Lett 1998; 102-3: 497-501.
95. Tilly JL. Apoptosis and ovarian function. Rev Reprod 1996; 1: 162-72.
96. Morita Y, Tilly JL. Oocyte apoptosis: Like sand through an hourglass. Dev Biol 1999; 213: 1-17.
97. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphin-gosine-1-phosphate therapy. Nat Med 2000; 6: 1109-14.
98. Paris F, Perez GI, Fuks Z, Haimovitz-Friedman A, Nguyen H, Bose M, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002; 8: 901-2.
99. Son WY, Yoon SH, Yoon HJ, Lee SM, Lim JH. Pregnancy outcome following transfer of human blastocysts vitrified on electron microscopy grids after induced collapse of the blastocoele. Hum Reprod 2003; 18: 137-9.
100. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 2005; 17: 299-308.
101. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003; 18: 90-5.
102. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004; 82: 1561-3.
103. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003; 18: 1588-97.
104. Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Curr Opin Obstet Gynecol 2005; 17: 21-6.
105. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347-53.
106. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril 2006; 85: 277-84.
107. Pickering SJ, Braude PR, Johnson MH, Cant A, Currie J. Transient cooling to room temperature can cause irreversible disruption of the meiotic spindle in the human oocyte. Fertil Steril 1990; 54: 102-8.
108. Gosden RG. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 2005; 34: 60-3.
109. Dittrich R, Maltaris T. A simple freezing protocol for the use of an open freezing system for cryopreservation of ovarian tissue. Cryobiology 2006; 52: 166.
110. Maltaris T, Dimmler A, Muller A, Binder H, Hoffmann I, Kohl J, et al. The use of an open-freezing system with self-seeding for cryopreservation of mouse ovarian tissue. Reprod Domest Anim 2005; 40: 250-4.
111. Oktay K, Newton H, Aubard Y, Salha O, Gosden RG. Cryopreservation of immature human oocytes and ovarian tissue: An emerging technology? Fertil Steril 1998; 69: 1-7.
112. Maltaris T, Dimmler A, Muller A, Hoffmann I, Beckmann MW, Dittrich R. Comparison of two freezing protocols in an open freezing system for cryopreservation of rat ovarian tissue. J Obstet Gynaecol Res 2006; 32: 273-9.
113. Newton H, Aubard Y, Rutherford A, Sharma V, Gosden R. Low temperature storage and grafting of human ovarian tissue. Hum Reprod 1996; 11: 1487-91.
114. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405-10.
115. Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353: 318-21.
116. Oktay K, Buyuk E, Veeck L, Zaninovic N, Xu K, Takeuchi T, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 363: 837-40.
117. Eppig JJ, O'Brien MJ. Development in vitro of mouse oocytes from primordial follicles. Biol Reprod 1996; 54: 197-207.
118. Gougeon A. Dynamics of follicular growth in the human: A model from preliminary results. Hum Reprod 1986; 1: 81-7.
119. Kim SS, Soules MR, Battaglia DE. Follicular development, ovulation, and corpus luteum formation in cryopreserved human ovarian tissue after xenotransplantation. Fertil Steril 2002; 78: 77-82.
120. Maltaris T, Kaya H, Hoffmann I, Mueller A, Beckmann MW, Dittrich R. Comparison of xenografting in SCID mice and LIVE/DEAD assay as a predictor of the developmental potential of cryopreserved ovarian tissue. In Vivo 2006; 20: 11-6.
121. Sonmezer M, Shamonki MI, Oktay K. Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res 2005; 322: 125-32.
122. Shaw JM, Bowles J, Koopman P, Wood EC, Trounson AO. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients. Hum Reprod 1996; 11: 1668-73.
123. Kim SS. Fertility preservation in female cancer patients: Current developments and future directions. Fertil Steril 2006; 85: 1-11.
124. Mueller A, Maltaris T, Dimmler A, Hoffmann I, Beckmann MW, Dittrich R. Development of sex cord stromal tumors after heterotopic transplantation of cryopreserved ovarian tissue in rats. Anticancer Res 2005; 25: 4107-11.
125. Go KJ. Better by half: The pursuit of haploidization. Embryol Newsl 2003; 6: 1-9.
126. Nagy ZP, Chang CC. Current advances in artificial gametes. Reprod Biomed Online 2005; 11: 332-9.
127. Sanger WG, Olson JH, Sherman JK. Semen cryobanking for men with cancer-criteria change. Fertil Steril 1992; 58: 1024-7.
128. Shin D, Lo KC, Lipshultz LI. Treatment options for the infertile male with cancer. J Natl Cancer Inst Monogr 2005; 34: 48-50.
129. Schrader M, Muller M, Straub B, Miller K. Testicular sperm extraction in azoospermic patients with gonadal germ cell tumors prior to chemotherapy-a new therapy option. Asian J Androl 2002; 4: 9-15.
130. Schmiegelow ML, Sommer P, Carlsen E, Sonksen JO, Schmiegelow K, Muller JR. Penile vibratory stimulation and electroejaculation before anticancer therapy in two pubertal boys. J Pediatr Hematol Oncol 1998; 20: 429-30.
131. Brougham MF, Kelnar CJ, Sharpe RM, Wallace WH. Male fertility following childhood cancer: Current concepts and future therapies. Asian J Androl 2003; 5: 325-37.
132. Park YS, Lee SH, Song SJ, Jun JH, Koong MK, Seo JT. Influence of motility on the outcome of in vitro fertilization/intracytoplasmic sperm injection with fresh vs. frozen testicular sperm from men with obstructive azoospermia. Fertil Steril 2003; 80: 526-30.
133. Lass A, Akagbosu F, Brinsden P. Sperm banking and assisted reproduction treatment for couples following cancer treatment of the male partner. Hum Reprod Update 2001; 7: 370-7.
134. Hallak J, Sharma RK, Thomas AJ Jr, Agarwal A. Why cancer patients request disposal of cryopreserved semen specimens posttherapy: A retrospective study. Fertil Steril 1998; 69: 889-93.
135. Kurdoglu B, Wilson G, Parchuri N, Ye WS, Meistrich ML. Protection from radiation-induced damage to spermatogenesis by hormone treatment. Radiat Res 1994; 139: 97-102.
136. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19: 159-62.
137. Thomson AB, Anderson RA, Irvine DS, Kelnar CJ, Sharpe RM, Wallace WH. Investigation of suppression of the hypo-thalamic-pituitary-gonadal axis to restore spermatogenesis in azoospermic men treated for childhood cancer. Hum Reprod 2002; 17: 1715-23.
138. Kamischke A, Kuhlmann M, Weinbauer GF, Luetjens M, Yeung CH, Kronholz HL, et al. Gonadal protection from radiation by GnRH antagonist or recombinant human FSH: A controlled trial in a male nonhuman primate (Macaca fascicularis). J Endocrinol 2003; 179: 183-94.
139. Boekelheide K, Schoenfeld HA, Hall SJ, Weng CC, Shetty G, Leith J, et al. Gonadotropin-releasing hormone antagonist (Cetrorelix) therapy fails to protect nonhuman primates (Macaca arctoides) from radiation-induced spermatogenic failure. J Androl 2005; 26: 222-34.
140. Kelnar CJ, McKinnell C, Walker M, Morris KD, Wallace WH, Saunders PT, et al. Testicular changes during infantile 'quiescence' in the marmoset and their gonadotrophin dependence: A model for investigating susceptibility of the prepubertal human testis to cancer therapy? Hum Reprod 2002; 17: 1367-78.
141. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: Who is at risk and what can be offered? Lancet Oncol 2005; 6: 209-18.
142. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. Proc Natl Acad Sci U S A 1994; 91: 11298-302.
143. Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for preservation of male fertility. J Natl Cancer Inst Monogr 2005; 34: 51-6.
144. Brinster CJ, Ryu BY, Avarbock MR, Karagenc L, Brinster RL, Orwig KE. Restoration of fertility by germ cell transplantation requires effective recipient preparation. Biol Reprod 2003; 69: 412-20.
145. Schlatt S, Rosiepen G, Weinbauer GF, Rolf C, Brook PF, Nieschlag E. Germ cell transfer into rat, bovine, monkey and human testes. Hum Reprod 1999; 14: 144-50.
146. Frederickx V, Michiels A, Goossens E, De Block G, Van Steirteghem AC, Tournaye H. Recovery, survival and functional evaluation by transplantation of frozen-thawed mouse germ cells. Hum Reprod 2004; 19: 948-53.
147. Jahnukainen K, Hou M, Petersen C, Setchell B, Soder O. Intratesticular transplantation of testicular cells from leukemic rats causes transmission of leukemia. Cancer Res 2001; 61: 706-10.
148. Tesarik J, Bahceci M, Ozcan C, Greco E, Mendoza C. Restoration of fertility by in vitro spermatogenesis. Lancet 1999; 353: 555-6.
149. Lee DR, Kim KS, Yang YH, Oh HS, Lee SH, Chung TG, et al. Isolation of male germ stem cell-like cells from testicular tissue of non-obstructive azoospermic patients and differentiation into haploid male germ cells in vitro. Hum Reprod 2006; 21: 471-6.
150. Lutchman, Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005; 11: 69-89.
151. van Rooij IA, Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, Velde, ER. Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 2003; 79: 482-8.
152. Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, et al. The endocrinology of the menopausal transition: A cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995; 80: 3537-45.
153. Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995; 64: 991-4.
154. Lee SJ, Lenton EA, Sexton L, Cooke ID. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Hum Reprod 1988; 3: 851-5.
155. Muttukrishna S, Knight PG. Inverse effects of activin and inhibin on the synthesis and secretion of FSH and LH by ovine pituitary cells in vitro. J Mol Endocrinol 1991; 6: 171-8.
156. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: A study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996; 81: 2742-5.
157. Munz W, Hammadeh ME, Seufert R, Schaffrath M, Schmidt W, Pollow K. Serum inhibin A, inhibin B, pro-alpha C, and activin A levels in women with idiopathic premature ovarian failure. Fertil Steril 2004; 82: 760-2.
158. Seifer DB, Scott RT Jr, Bergh PA, Abrogast LK, Friedman CI, Mack CK, et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril 1999; 72: 63-5.
159. van Rooij IA, Broekmans FJ, Velde, ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: A novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065-71.
160. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: A new marker for ovarian function. Reproduction 2006; 131: 1-9.
161. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: The role of anti-Mullerian hormone. Reproduction 2002; 124: 601-9.
162. Velde, ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002; 8: 141-54.
163. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987; 2: 645-7.
164. Hendriks DJ, Broekmans FJ, Bancsi LF, de Jong FH, Looman CW, Te Velde, ER. Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: A comparison with basal markers for ovarian reserve. Hum Reprod 2005; 20: 163-9.
165. Sharara FI, Scott RT Jr, Seifer DB. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol 1998; 179: 804-12.
166. Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertil Steril 1990; 53: 288-94.
167. Winslow KL, Toner JP, Brzyski RG, Oehninger SC, Acosta AA, Muasher SJ. The gonadotropin-releasing hormone agonist stimulation test-a sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil Steril 1991; 56: 711-7.
168. Fabregues F, Balasch J, Creus M, Carmona F, Puerto B, Quinto L, et al. Ovarian reserve test with human menopausal gona-dotropin as a predictor of in vitro fertilization outcome. J Assist Reprod Genet 2000; 17: 13-9.
169. Fanchin R, de Ziegler D, Olivennes F, Taieb J, Dzik A, Frydman R. Exogenous follicle stimulating hormone ovarian reserve test (EFORT): A simple and reliable screening test for detecting 'poor responders' in in vitro fertilization. Hum Reprod 1994; 9: 1607-11.
170. Kwee J, Elting MW, Schats R, Bezemer PD, Lambalk CB, Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: Results of a prospective randomized study. Hum Reprod 2003; 18: 1422-7.
171. Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998; 69: 505-10.
172. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, Te Velde, ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: A randomized controlled trial. Hum Reprod 2005; 20: 611-5.
173. Ivarsson SA, Nilsson KO, Persson PH. Ultrasonography of the pelvic organs in prepubertal and postpubertal girls. Arch Dis Child 1983; 58: 352-4.
174. Andolf E, Jorgensen C, Svalenius E, Sunden B. Ultrasound measurement of the ovarian volume. Acta Obstet Gynecol Scand 1987; 66: 387-9.
175. Wallace WH, Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 2004; 19: 1612-7.
176. Schmidt KL, Byskov AG, Nyboe, Andersen A, Muller J, Yding, Andersen C. Density and distribution of primordial follicles in single pieces of cortex from 21 patients and in individual pieces of cortex from three entire human ovaries. Hum Reprod 2003; 18: 1158-64.
177. Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, Velde, ER. Predictors of poor ovarian response in in vitro fertilization: A prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002; 77: 328-36.
178. Siimes MA, Rautonen J. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies. Cancer 1990; 65: 1303-6.
179. Wallace EM, Groome NP, Riley SC, Parker AC, Wu FC. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: A prospective longitudinal study. J Clin Endocrinol Metab 1997; 82: 3111-5.
180. Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril 2001; 75: 705-10.
181. Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril 2005; 83: 897-901.
182. Agarwal A, Ranganathan P, Kattal N, Pasqualotto F, Hallak J, Khayal S, et al. Fertility after cancer: A prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 2004; 81: 342-8.
183. Schmidt KL, Larsen E, Bangsboll S, Meinertz H, Carlsen E, Andersen AN. Assisted reproduction in male cancer survivors: Fertility treatment and outcome in 67 couples. Hum Reprod 2004; 19: 2806-10.